Latest Biotech News

Avalyn Pharma filed for an initial public offering as a pulmonary fibrosis biotech developing inhaled formulations of approved oral medicines. The company’s filing signals it is seeking...

Sidewinder Therapeutics, a next-generation antibody-drug conjugate startup, secured an oversubscribed $137 million Series B to fund development of bispecific ADCs. The company plans to move a lead...

New coverage highlights how large language models are being applied to biology and chemistry research using the growing availability of large molecular and experimental datasets. The article...

Researchers reported in Cell Research that GSK3α acts as a universal “stemness checkpoint” regulating stem cell identity across multiple stem cell types and developmental contexts. The work...

Scientists at UCSF published a high-resolution single-cell spatiotemporal atlas of the human maternal–fetal interface in Nature, mapping cell types across normal pregnancy and linking them to...

The FDA’s 2027 budget proposal lays out regulatory reforms aimed at expediting development and review, including making the rare pediatric disease priority review voucher program permanent. If...

CellCarta and Lunit entered a partnership to integrate AI pathology solutions into clinical trial workflows and biomarker development. The collaboration pairs CellCarta’s global clinical pathology...

Syneron Bio secured more than $250 million in venture funding as it builds a platform in macrocyclic peptides, and also announced a multi-billion-dollar deal with AstraZeneca. The financing and...

Multiple genetics studies are moving GLP-1 obesity therapy toward more individualized targeting by linking patient variants to weight-loss magnitude and side-effect risk. 23andMe Research...

A new mechanistic study identifies a neuroblastoma survival pathway that may be druggable by disrupting neuronal nitric oxide synthase (nNOS) signaling. Researchers from The Hebrew University of...

Salk Institute researchers unveiled a scalable stem-cell platform to generate mitochondrial DNA mutant mice, addressing a key bottleneck in modeling the full diversity of inherited mitochondrial...

A new smart contact lens approach pairs continuous intraocular pressure (IOP) monitoring with closed-loop, adaptive drug delivery for glaucoma. In Science Translational Medicine, Terasaki...

A study from MD Anderson identifies DPY30 as a key epigenetic regulator linked to genomic stability under DNA replication stress in pancreatic tumors. Researchers at The University of Texas MD...

ASH and ISTH released new clinical guidance for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism (VTE) outside cardiac indications. Published in Blood Advances,...

University Hospitals Seidman Cancer Center launched S2419 BioFront, a Phase III program that integrates a gut microbiome intervention into an advanced kidney cancer treatment protocol. The study...

Sidewinder Therapeutics secured $137 million in an oversubscribed Series B round to advance bispecific antibody-drug conjugates toward clinical testing. Backed by OrbiMed and multiple investors,...

Gilead agreed to acquire German ADC specialist Tubulis to expand its antibody-drug conjugate capabilities, with deal terms reaching up to $5 billion. The acquisition includes $3.15 billion...

Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, adding the FDA-approved Vykat XR (diazoxide choline) therapy for Prader-Willi syndrome hyperphagia. Under the...

Gilead Sciences agreed to acquire German ADC specialist Tubulis for $3.15 billion upfront, with up to $1.85 billion in milestones, expanding the company’s antibody-drug conjugate pipeline beyond...

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, aiming to broaden its marketed endocrinology and rare-disease portfolio. The acquisition includes Vykat XR (diazoxide...